Unlock instant, AI-driven research and patent intelligence for your innovation.

A biomimetic drug carrier combined with photoexcitation and cell ferroptosis induction and its preparation method and application

A technology of ferroptosis and light excitation, which is applied in the direction of drug combinations, pharmaceutical formulas, medical preparations of non-active ingredients, etc., can solve the problem of uneven distribution of dihydroartemisinin tumor sites, achieve good aqueous solution dispersion, improve effective Action concentration, effect of protecting growth

Active Publication Date: 2021-10-08
SHANGHAI UNIV
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] The purpose of the present invention is to provide a biomimetic drug carrier combined with light excitation and cell ferroptosis induction, which improves the ferroptosis induction effect of the ferroptosis inducer dihydroartemisinin, and solves the uneven distribution of dihydroartemisinin in tumor sites Moreover, by combining with the transition metal-tannic acid network structure with photothermal conversion, it has photoexcitable properties under laser irradiation, and the surface-modified cell membrane improves the targeting and biocompatibility of biomimetic drug carriers It has a good effect of inhibiting the growth of tumor cells and escaping the immune system

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A biomimetic drug carrier combined with photoexcitation and cell ferroptosis induction and its preparation method and application
  • A biomimetic drug carrier combined with photoexcitation and cell ferroptosis induction and its preparation method and application
  • A biomimetic drug carrier combined with photoexcitation and cell ferroptosis induction and its preparation method and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0055] Embodiment 1: Preparation of CM / DHA@ZIF-90-Fe-TA

[0056] (1) Dissolve 10 mg of dihydroartemisinin in 2 ml of N, N-dimethylformamide and 43.8 mg of zinc acetate in 2 ml of N, N-dimethylformamide, mix them, stir at room temperature for 2 hours, use The zinc ion of zinc acetate and dihydroartemisinin form a coordination bond;

[0057] (2) Dissolve 38.6mg of 2-imidazole formaldehyde in 2ml of N,N-dimethylformamide and stir at 70°C until completely dissolved;

[0058] (3) Mix the above two solutions, stir and react for 5 minutes, add 10ml N, N-dimethylformamide to it, continue stirring for 20 minutes, centrifuge at 12000rmp for 15 minutes, and then use N, N-dimethylformamide respectively Dimethyl formamide and ethanol were washed three times to remove unreacted reagents, and dried at room temperature to obtain DHA@ZIF-90 carrier;

[0059] (4) 50 mg of tannic acid is dissolved into 5 ml of deionized water;

[0060] (5) Add 100mg of DHA@ZIF-90 carrier, ultrasonically oscil...

Embodiment 2

[0063] Embodiment 2: Preparation of CM / DHA@ZIF-90-Fe-TA

[0064] (1) Dissolve 50 mg of dihydroartemisinin in 4 ml of N, N-dimethylformamide and 43.8 mg of zinc acetate dissolved in 2 ml of N, N-dimethylformamide, mix them, stir at room temperature for 2 hours, use The zinc ion of zinc acetate and dihydroartemisinin form a coordination bond;

[0065] (2) Dissolve 200mg of 2-imidazole formaldehyde in 100ml of N,N-dimethylformamide and stir at 70°C until completely dissolved;

[0066] (3) Mix the above two solutions, stir and react for 10 minutes, add 10ml N, N-dimethylformamide to it, continue stirring for 20 minutes, centrifuge at 12000rmp for 15 minutes, and then use N, N-dimethylformamide respectively Dimethyl formamide and ethanol were washed three times to remove unreacted reagents, and dried at room temperature to obtain DHA@ZIF-90 carrier;

[0067] (4) 100mg of tannic acid is dissolved in 5ml of deionized water;

[0068] (5) Add 100mg of DHA@ZIF-90 carrier, ultrasonica...

Embodiment 3

[0071] Embodiment 3: Preparation of CM / DHA@ZIF-90-Fe-TA

[0072] (1) Dissolve 200mg of dihydroartemisinin in 10ml of N,N-dimethylformamide and 300mg of zinc acetate in 10ml of N,N-dimethylformamide solution, stir at room temperature for 2h, and use acetic acid The zinc ion of zinc and dihydroartemisinin form a coordination bond;

[0073] (2) Dissolve 200mg of 2-imidazole formaldehyde in 10ml of N,N-dimethylformamide, and stir at 70°C until completely dissolved;

[0074] (3) Mix the above two solutions, stir and react for 5 minutes, add 10ml N, N-dimethylformamide to it, continue stirring for 20 minutes, centrifuge at 12000rmp for 15 minutes, and then use N, N-dimethylformamide respectively Dimethyl formamide and ethanol were washed three times to remove unreacted reagents, and dried at room temperature to obtain DHA@ZIF-90 carrier;

[0075] (4) 200mg tannic acid is dissolved into 5ml deionized water;

[0076] (5) Add 100mg of DHA@ZIF-90 carrier, ultrasonically oscillate eve...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a biomimetic drug carrier induced by photoexcitation combined with cell ferroptosis. The biomimetic drug carrier includes cell membrane, transition metal and tannic acid network structure, mitochondria-targeted zeolite imidazole skeleton and The ferroptosis inducer dihydroartemisinin embedded in a zeolitic imidazole framework. The invention also discloses the preparation method of the bionic drug carrier and its application in the preparation of drugs for inhibiting tumor cell proliferation. The biomimetic drug carrier improves the induction effect of dihydroartemisinin on ferroptosis of tumor cells, and realizes the targeted delivery of dihydroartemisinin to the mitochondria of tumor cells in combination with the synergistic treatment of photothermal therapy and ferroptosis. It not only solves the problem of the consumption of dihydroartemisinin transported in the body, reduces the toxic and side effects on normal organs, but also avoids the exogenous toxicity of nanomaterials, escapes the interception and clearance of the immune system, and makes the drug treatment targeted and biocompatibility.

Description

technical field [0001] The invention relates to a targeting carrier, in particular to a biomimetic drug carrier induced by light excitation combined with cell ferroptosis and its preparation method and application. Background technique [0002] Tumor has become the number one "killer" that threatens human health. Regardless of age, gender, social status, etc., cancer directly or indirectly affects human life. It is not only a personal health issue, but also a social issue that has been closely watched by families and society. Therefore, research on tumor cells has always been a hot spot in recent scientific research. [0003] Ferroptosis is a recently discovered form of regulated cell death. Different from traditional cell death programs such as necrosis, apoptosis, and pyroptosis, ferroptosis is caused by the accumulation of iron-dependent and highly lethal lipid peroxides. cell death program. The occurrence of ferroptosis can be induced by two types of small molecules: ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K9/51A61K47/46A61K47/02A61K47/26A61K41/00A61K31/366A61P35/00
CPCA61K9/5115A61K9/5123A61K9/5176A61K31/366A61K41/0052A61P35/00A61K2300/00
Inventor 陈雪瑞王艳丽詹琳薛强华李亚杰徐亚军
Owner SHANGHAI UNIV